E. Gizeli participated in three web-conferences as invited speaker.

1. at the 18th National Congress of the Greek Society of Clinical Chemistry and Biochemistry Conference on 15-17 October 2020;
2. at the 1st EFLM/AFCB Conference on Laboratory Medicine for Mobile Societies (LM4MS) on 18-20 February 2021

(both conferences were organised under the auspices of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC);

3. Nanotexnology 2021: International Conference on Nano-technologies, Organic Electronics and Nanomedicine (abstract).

Biosensors Lab receives funding from HFRI under the 4th call for “Interventions to address the economic and social consequences of the COVID-19 pandemic”.

Biosensors Lab received funding to develop a rapid diagnostic tool for COVID-19 antibodies detection directly in patients samples. The project, which has a duration of 12 months, will be carried out in collaboration with clinical partners at the Univ. of Crete.

The Human Frontier Science Program posts our recent publication on “Hybrid Sensor Device for Simultaneous Surface Plasmon Resonance and Surface Acoustic Wave Measurements” that appeared in Sensors 2020, Vol 20, pp. 6177, in the HFSP News and Events.

Prof. Electra Gizeli interviewed at “Kathimetini” about the rapid COVID-19 test developed in Biosensors’ lab (check News menu for more).

Prof. Electra Gizeli talks to Y. Elafros at “Kathimetini” for the novel device and rapid molecular test developed in Biosensors’ lab for COVID-19 and for applications at the point-of-care.

Hybrid Sensor Device for Simultaneous Surface Plasmon Resonance and Surface Acoustic Wave Measurements by Samarentsis et al has just been published.

“Hybrid Sensor Device for Simultaneous Surface Plasmon Resonance and Surface Acoustic Wave Measurements” published on Sensors

Prof. Gizeli delivered an invited talk at the 18th National congress of the Greek society of clinical chemistry-biochemistry entitled “A novel molecular diagnostic point-of-care test for SARS-CoV-2.

The lab’s portable molecular diagnostic device ready to be commercially available for the detection of SARS-CoV-2 in the next few months, from FORTH’s spin off company BioPix-T.